Facebook
Instagram
Twitter
Vimeo
Youtube
Sign in
Business News
Top News
Money
Economy
Privacy Policy
Terms of Service
Disclaimer
Contact Us
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Password recovery
Recover your password
your email
Search
Business News
Top News
Money
Economy
Privacy Policy
Terms of Service
Disclaimer
Contact Us
Search
Home
Eisai, Biogen’s Alzheimer’s drug price should not dent demand – analysts
FILE PHOTO: A sign marks a Biogen facility in Massachusetts
FILE PHOTO: A sign marks a Biogen facility in Massachusetts
FILE PHOTO: A sign marks a Biogen facility in Cambridge, Massachusetts, U.S. January 26, 2017. REUTERS/Brian Snyder
- Advertisment -
Most Read
Eyeing China in the Pacific, US studies explosives to make missiles fly farther
August 3, 2023
For investors, green companies still hard to find with new emissions reporting rules
August 3, 2023
Pope, in Portugal to rally young Catholics, says Church needs purification
August 3, 2023
Wall Street ends down, investors step back after Fitch US rating cut
August 2, 2023
